{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Records will be assessed at baseline and prospectively while on study.","groups":[{"description":"Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.\n\ndeferasirox : Given orally\n\nlaboratory biomarker analysis : Correlative studies\n\nenzyme-linked immunosorbent assay : Correlative studies","id":"OG000","title":"Arm I"},{"description":"treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis","id":"OG001","title":"Correlative"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline, up to 6 months","title":"Cumulative Incidence of Documented Bacterial, Fungal, and Viral Infections","type":"SECONDARY","unitOfMeasure":"Participants"}